The DOI matches its Crossref record.
Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 21
- Colombo, 1996, Paclitaxel induces significant changes in epidoxorubicin distribution in mice, Ann Oncol, 7, 801, 10.1093/oxfordjournals.annonc.a010758 · doi:10.1093/oxfordjournals.annonc.a010758
- Gianni, 1995, Paclitaxel by three-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study [see comments], J Clin Oncol, 13, 2688, 10.1200/JCO.1995.13.11.2688 · DOI · Paper page
- Amadori, 1996, A phase I-II study of paclitaxel and doxorubicin in the treatment of advanced breast cancer, Semin Oncol, 23, 19
- Gianni, 1997, Experience at the Istituto Nazionale Tumori with paclitaxel in combination with doxorubicin in women with untreated breast cancer, Semin Oncol, 24, S1
- demons, 1997, Review of recent trials of chemotherapy for advanced breast cancer: The taxanes, Eur J Cancer, 33, 2183, 10.1016/S0959-8049(97)00262-1 · doi:10.1016/s0959-8049(97)00262-1
- Khayat, 1997, Docetaxel in combination chemotherapy for metastatic breast cancer. [Review] [30 refs], Semin Oncol, 24, S13
- Gehl, 1996, Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic, Ann Oncol, 7, 687, 10.1093/oxfordjournals.annonc.a010717 · DOI · Paper page
- Hortobagyi, 1997, Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer Semin Oncol, 24, S17
- Dombernowsky, 1996, Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer. [Review] [17 refs], Semin Oncol, 23, 13
- Holmes, 1996, Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer, J Clin Oncol, 14, 2713, 10.1200/JCO.1996.14.10.2713 · DOI · Paper page
- Gianni, 1997, Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer, J Clin Oncol, 15, 1906, 10.1200/JCO.1997.15.5.1906 · DOI
- Broggini, 1984, Activity and distribution of i. and oral 4-demethoxydaunorubicin in murine experimental tumors, Cancer Treat Rep, 68, 739
- Holmes, 1995, Update: the M. D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma, Semin Oncol, 22, 9
- Eisenhauer, 1998, The taxoids. Comparative clinical pharmacology and therapeutic potential. [Review] [188 refs], Drugs, 55, 5, 10.2165/00003495-199855010-00002 · DOI · Paper page
- Bhalla, 1994, Characterization of a human myeloid leukemia cell line highly resistant to taxol, Leukemia, 8, 465
- Parekh, 1997, The transport and binding of Taxol. [Review] [47 refs], Gen Pharmacol, 29, 167, 10.1016/S0306-3623(97)89716-9 · DOI
- Rischin, 1996, Cremophor pharma- cokinetics in patients receiving three-, six-, and 24-hour infusions of paclitaxel, J Natl Cancer Inst, 88, 1297, 10.1093/jnci/88.18.1297 · doi:10.1093/jnci/88.18.1297
- Gottesman, 1993, Biochemistry of multidrug resistance mediated by the multidrug transporter. [Review] [348 refs], Annu Rev Biochem, 62, 385, 10.1146/annurev.bi.62.070193.002125 · DOI · Paper page
- Bradley, 1994, P-glycoprotein, multidrug resistance and tumor progression. [Review] [46 refs], Cancer Metastasis Rev, 13, 223, 10.1007/BF00689638 · DOI · Paper page
- Nygren, 1995, The cytotoxic activity of taxol in primary cultures of tumour cells from patients is partly mediated by cremophor EL, Br J Cancer, 71, 478, 10.1038/bjc.1995.97 · doi:10.1038/bjc.1995.97
- Webster, 1997, Plasma concentrations of polysorbate 80 measured in patients following admin istration of docetaxel or etoposide, Cancer Chemoth Pharmacol, 39, 557, 10.1007/s002800050615 · doi:10.1007/s002800050615
Cited by
Strategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
Pharmacological Effects of Formulation Vehicles: Implications for Cancer Chemotherapy
ten Tije, A. J., Verweij, J., Loos, W. J., & Sparreboom, A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00005 · Cited by 591
Role of Formulation Vehicles in Taxane Pharmacology
van Zuylen, L., Verweij, J., & Sparreboom, A. (2001) · Investigational New Drugs · doi:10.1023/a:1010618632738 · Cited by 293
Agbulut, O. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(03)00281-5 · Cited by 68
Metadata
- Authors
- Colombo, T., Parisi, I., Zucchetti, M., Sessa, C., Goldhirsch, A., & D’lncalci, M.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 1999-04
- Volume
- 10
- Issue
- 4
- Pages
- 391-395
- ISSN
- 0923-7534
- Cited by
- 31
- References
- 0
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 7572 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin. https://app.cochat.ai/papers/10.1023/a:1008309916974
- The paper
- Colombo, T., Parisi, I., Zucchetti, M., Sessa, C., Goldhirsch, A., & D’lncalci, M. (1999). Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin. Annals of Oncology. https://doi.org/10.1023/a%3A1008309916974
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.